Nevertheless, further studies involving TSLP/TSLPR blockade combined with therapeutic options such as MAP kinase inhibitors (targeting tumor cells) or immune checkpoint therapies (targeting immune cells) are required. Here, CRLF2 is linked to neoplasm.